Skip to content
Elite Peptides

[ GLP-1 / incretin research ]

Retatrutide vs tesamorelin: two different metabolic-research targets

A research-reference comparison of two GLP-class compounds we supply — retatrutide, studied as a triple GLP-1 / GIP / glucagon agonist, and tesamorelin, a GHRH-analogue — how their receptor targets differ. Receptor-research framing only; research use only.

7 min read · Updated 22 July 2026

Retatrutide and tesamorelin research vials — two GLP-class metabolic-research compounds, independently HPLC-tested, COA on file

[ Research use only · Not for human consumption ]

Retatrutide vs tesamorelin.Both are catalogued under GLP-class & metabolic research peptides, so researchers new to the space often want to know how they relate — but they target entirely different receptor systems. This guide is a research-reference comparison for Australian researchers, framed strictly around receptor pharmacology. It makes no medical, therapeutic, weight-loss, or body-composition claim.

Different receptors entirely

Retatrutide is studied as a triple agonist of the GLP-1, GIP and glucagon receptors — the incretin / glucagon family. Tesamorelin is a GHRH-analogue acting on the growth-hormone-releasing-hormone receptor. Despite sharing the “metabolic-research” category label, they target different pathways: incretin/glucagon signalling versus the somatotrophic (GHRH) axis.

What the research reports for each

Retatrutide’s triple-agonist receptor pharmacology was reported by Coskun and colleagues (Cell Metabolism, 2022) and its first-in-human pharmacokinetics by Urva and colleagues (The Lancet, 2022). Tesamorelin’s stabilising chemistry and GHRH-receptor pharmacology were characterised by Ferdinandi and colleagues (Basic & Clinical Pharmacology & Toxicology, 2007) and Stanley and colleagues (The Journal of Clinical Endocrinology & Metabolism, 2011). Elite AU Peptides cites these as published research findings only. The retatrutide and tesamorelin guides cover each in depth.

Same category, different targets

Both appear in the metabolic / growth-hormone-axis research literature and both are catalogued under GLP-class & metabolic research peptides, which is why they are compared — but the short answer is: same catalogue category, different receptor targets. The GLP-1 research peptides pillar sets out the wider incretin-research space.

Verification and compliance

Every batch of each compound is independently HPLC-tested by Janoshik before listing, with the certificate published in the lab-reports library. Neither is TGA-approved and neither is a therapeutic good; both are supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption, with no medical, therapeutic, weight-loss, or body-composition claim. This comparison is a research-reference summary, not a recommendation for any use.

[ Frequently asked ]

GLP-1 / incretin research — questions researchers ask.

What is the core difference between retatrutide and tesamorelin?
They act on entirely different receptor systems. Retatrutide is studied as a triple agonist of the GLP-1, GIP and glucagon receptors (the incretin / glucagon family); tesamorelin is a GHRH-analogue acting on the growth-hormone-releasing-hormone receptor. Despite sharing the “metabolic-research” category, they target different pathways. This is a research-reference comparison, not a recommendation for any use.
What research supports each compound?
Retatrutide's triple-agonist receptor pharmacology was reported by Coskun and colleagues (Cell Metabolism, 2022) and its first-in-human PK by Urva and colleagues (The Lancet, 2022). Tesamorelin's stabilising chemistry and GHRH-receptor pharmacology were characterised by Ferdinandi and colleagues (Basic & Clinical Pharmacology & Toxicology, 2007) and Stanley and colleagues (JCEM, 2011). We cite these as published research findings only.
Why compare them if they target different receptors?
Both appear in the metabolic / growth-hormone-axis research literature and both are catalogued under GLP-class & metabolic research peptides, so researchers new to the space often want to know how they relate. The short answer: same catalogue category, different receptor targets — incretin/glucagon versus GHRH.
Are retatrutide or tesamorelin TGA-approved?
No. Neither is TGA-approved and neither is a therapeutic good. Both are supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption, with no medical, therapeutic, weight-loss, or body-composition claim.
How are they verified and shipped?
Every batch of each compound is independently HPLC-tested by Janoshik Analytical before listing, with the certificate published in the lab-reports library. Dispatched AU-domestic; free shipping over $100; same-day dispatch before 12pm AEST. Supplied strictly for laboratory research use only.

Elite AU Peptides supplies research peptides and related compounds for laboratory and in-vitro research use only. Products are not therapeutic goods, are not TGA-approved, and are not for human or animal consumption. Nothing on this site constitutes medical advice or a therapeutic claim. Purchasers must be 18 years or older and are responsible for complying with all applicable laws in their jurisdiction.